B&K CORPORATION

B&K CORPORATION LIMITED, established in 2012, is a national high-tech enterprise primarily focused on the research and development of biological macromolecule drugs. B&K CORPORATION boasts a strong R&D technical team, with leading figures having extensive experience in molecular biology, innovative drug, and vaccine development; over 80% of the team holds doctoral or master’s degrees. The company's current project, the platelet-derived growth factor TPG, has obtained clinical approval from the National Medical Products Administration for its first indication and is undergoing Phase I clinical trials. B&K CORPORATION continues to deepen its cooperation with top global scientific research institutions and has established multiple technology platforms, including yeast expression platforms, mRNA platforms, and nanocapsule delivery systems. In the future, the company will rapidly advance multiple self-developed product pipelines, including TPG and mRNA vaccines, for dual IND applications and clinical studies in both China and the United States.